Skip to main content
Clinical Trials/NCT03591861
NCT03591861
Terminated
Not Applicable

Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

Washington University School of Medicine1 site in 1 country2 target enrollmentMay 1, 2019

Overview

Phase
Not Applicable
Intervention
Ketogenic diet
Conditions
Pediatric Brain Tumor
Sponsor
Washington University School of Medicine
Enrollment
2
Locations
1
Primary Endpoint
Feasibility of combining a ketogenic diet with chemotherapy in children with relapsed brain tumors as measured by the number of patients who can recruited with 3 years
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

The investigators will develop the concept of a sex-specific therapeutic intervention for gliomas that is based upon dietary carbohydrate restriction. The investigators will integrate metabolomics tools and FDG-PET imaging to validate the ketogenic diet on a sex-specific basis.

Registry
clinicaltrials.gov
Start Date
May 1, 2019
End Date
November 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of a recurrent primary brain tumor with no curative therapy available.
  • Measurable disease using pediatric Response Assessment in Neuro-Oncology Criteria (RANO) criteria.
  • Life expectancy \> 12 weeks
  • Prior treatment with radiation alone, chemotherapy alone or combined radiation and chemotherapy is allowed.
  • Patient is \< 21 years of age
  • Normal bone marrow and organ function as defined below:
  • Leukocytes ≥ 3,000/mcL
  • Absolute neutrophil count ≥ 1,500/mcl
  • Platelets ≥ 100,000/mcl
  • Total bilirubin ≤ 1.5 x IULN

Exclusion Criteria

  • Patient does not have any of the following conditions as they are contraindicated for ketogenic diet:
  • Primary and secondary carnitine deficiency
  • Carnitine palmitoyltransferase I or II deficiency
  • Carnitine translocase deficiency
  • Mitochondrial β-oxidation defects
  • Pyruvate carboxylase deficiency
  • Glycogen storage diseases
  • Ketolysis defects
  • Ketogenesis defects
  • Porphyria

Arms & Interventions

Ketogenic Diet

* Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures) * Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months * Laboratory studies prior to hospital admission and then at each follow-up visit * Hospital admission (3-5 day) to start the ketogenic diet * Standard of care chemotherapy with BCNU for up to 2 years * Ketogenic diet can continue for up to 2 years

Intervention: Ketogenic diet

Ketogenic Diet

* Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures) * Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months * Laboratory studies prior to hospital admission and then at each follow-up visit * Hospital admission (3-5 day) to start the ketogenic diet * Standard of care chemotherapy with BCNU for up to 2 years * Ketogenic diet can continue for up to 2 years

Intervention: BCNU

Outcomes

Primary Outcomes

Feasibility of combining a ketogenic diet with chemotherapy in children with relapsed brain tumors as measured by the number of patients who can recruited with 3 years

Time Frame: Through completion of enrollment of all participants (estimated to be 3 years)

* The study will be defined as being feasible if all 15 patients can be recruited within 3 years * Please note that feasibility of the study is dependent on both primary outcome measures

Feasibility of combining a ketogenic diet with chemotherapy in children with relapsed brain tumors as measured by if at least 80% of the patients comply with the intervention

Time Frame: Up to 2 years

-The study will be defined as being feasible if at least 80% of the patients comply with the intervention as defined as achieving 80% of the targeted level of ketosis as assessed from laboratory measures and 80% of the planned BCNU doses --Please note that feasibility of the study is dependent on both primary outcome measures

Secondary Outcomes

  • Tolerability of combining a ketogenic diet with chemotherapy in male children with relapsed brain tumors versus female children with relapsed brain tumors as measured by toxicity(Up to 2 years)
  • Tumor response of male children with relapsed brain tumors to a ketogenic diet combined with chemotherapy versus female children with relapsed brain tumors as measured by progression-free survival (PFS)(Up to 10 years)

Study Sites (1)

Loading locations...

Similar Trials